EMA: Pilot Programme for Breakthrough Device

16.01.2026

News

The EMA plans to launch a pilot programme in Q2 2026 to implement the guidance for breakthrough devices issued in December 2025.

The initiative aims to speed up access to highly innovative medical devices and IVDs while upholding safety and performance standards. BtX manufacturers will benefit from enhanced regulatory support and priority scientific advice from EMA expert panels. Detailed guidance for manufacturers will be published ahead of the pilot’s start. .

Source:

EMA: Human regulatory: overview - Medical devices

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

What do Typical Manufacturing Processes for Sterile Products look like?

09.02.2026

Question of the Week

What do Typical Manufacturing Processes for Sterile Products look like?

Here's the answer:

Human Resource Management as a Key to Success

09.02.2026

LOGFILE Feature

Human Resource Management as a Key to Success

The pharmaceutical industry in Germany and other countries, too, faces considerable challenges in the area of human resource management. These problems have far-reaching implications for the competitiveness and innovative power of the industry.

EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

06.02.2026

News

EMA: Reflection Paper on the Qualification of Non-Mutagenic Impurities (NMIs)

The EMA has published a new reflection paper outlining its current thinking on the qualification of non-mutagenic impurities (NMIs). The paper addresses recommended approaches for evaluating the safety of new or increased impurity levels, particularly when such impurities exceed the ICH Q3A/Q3B qualification thresholds and are identified after completion of non-clinical toxicology studies.

EMA: Discussions on the Revised ERA Guideline

06.02.2026

News

EMA: Discussions on the Revised ERA Guideline

During the second industry stakeholder webinar on the revised guideline on environmental risk assessment (ERA) for medicinal products for human use, the European Medicines Agency (EMA) addressed key implementation challenges observed during the first year of application.

EMA: New Q&A on Product Lifecycle Management (PLCM)

30.01.2026

News

EMA: New Q&A on Product Lifecycle Management (PLCM)

The EMA has published new Questions & Answers on the use of the Product Lifecycle Management (PLCM) document, clarifying its role within the EU variations framework for post-approval quality changes.

EMA: New Q&A for Co-Processed Excipients

30.01.2026

News

EMA: New Q&A for Co-Processed Excipients

The EMA has published new Questions & Answers on co-processed excipients (CoPEs) used in solid oral dosage forms, introducing a harmonised, risk-based regulatory approach applicable to human and veterinary medicines.